Royalty Pharma (RPRX) Free Cash Flow (2019 - 2026)

Royalty Pharma has disclosed Free Cash Flow across 8 years of filings, most recently posting $265.9 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at $265.9 million, down 55.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $462.9 million (up 65.48% YoY), and the FY2025 annual result was $792.1 million, up 200.85% from the prior year.
• Free Cash Flow came in at $265.9 million for Q1 2026 at Royalty Pharma, up from $93.5 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $595.0 million in Q1 2025 to a low of -$777.5 million in Q3 2022.
• The 5-year median for Free Cash Flow is $265.9 million (2026), against an average of $152.7 million.
• Across the five-year window, Free Cash Flow jumped 1898.2% in 2022 and sank 501.15% in 2024, its largest moves.
• Royalty Pharma's Free Cash Flow stood at $319.7 million in 2022, then tumbled by 171.82% to -$229.6 million in 2023, then soared by 207.18% to $246.1 million in 2024, then sank by 62.02% to $93.5 million in 2025, then soared by 184.46% to $265.9 million in 2026.
• The last three Free Cash Flow figures came in at $265.9 million (Q1 2026), $93.5 million (Q4 2025), and -$259.3 million (Q3 2025), per Business Quant data.